<DOC>
	<DOC>NCT00999895</DOC>
	<brief_summary>The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).</brief_summary>
	<brief_title>A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis of schizophrenia (as per DSMIV), at least 6 months prior to enrolment in the study Subjects who have initiated a new antipsychotic treatment within the preceding 2 weeks Subjects whose prior and current antipsychotic treatment consists of any typical or atypical antipsychotic monotherapy Subjects fulfilling criteria for diagnosis of any other psychiatric condition (except from schizophrenia), as per DSMIV Axis Î™, concomitant organic mental disorder or mental retardation Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSMIV criteria and not in full remission Female subjects who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Switch of antipsychotic treatment</keyword>
	<keyword>Outcome evaluation</keyword>
	<keyword>monotherapy</keyword>
	<keyword>Greece</keyword>
</DOC>